R-DHA-oxaliplatin (R-DHAOx) versus R-DHA-cisplatin (R-DHAP) regimen in B-cell lymphoma treatment: A eight-year trajectory study.

Carole Lacout Corentin OrvainValérie SeegersManon De VriesMélanie MercierJonathan FarhiAline ClavertSylvain ThepotMarie-Pierre MolesNorbert IfrahMathilde Hunault-BergerAline Tanguy-Schmidt

Published in: European journal of haematology (2020)

Our study confirms that R-DHAOx regimen causes less nephrotoxicity than R-DHAP regimen.

Keyphrases

fatty acid
drug induced
replacement therapy